Provirus Load in Patients with Human T-Cell Leukemia Virus Type 1 Uveitis Correlates with Precedent Graves’ Disease and Disease Activities

Ayako Ono,1, 2 Eiko Ikeda,2 Manabu Mochizuki,2 Masao Matsuoka,3 Kazunari Yamaguchi,3 Takashi Sawada,4 Sumitaka Yamane,4 Shinken Tokudome5 and Toshiki Watanabe1, 6

1Department of Pathology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokane-dai, Minato-ku, Tokyo 108-8639, 2Department of Ophthalmology, Kurume University School of Medicine, 67 Asahimachi, Kurume 830-0011, 3Department of Internal Medicine, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-0811, 4Diagnostic Division, Tsukuba Research Laboratories, Eisai, Co., Ltd., 5-1-3 Tokodai, Tsukuba, 300-2635 and 5Department of Public Health, Nagoya City University Medical School, 1 Kawasumi, Mizuho, Mizuho-ku, Nagoya 467-0001

We previously demonstrated the increased provirus load in the peripheral blood of patients with human T-cell leukemia virus type 1 (HTLV-1) uveitis (HU). To delineate the relevance of the increased provirus load to clinical and immunologic parameters, we studied the correlation between them. Seventy-nine HU patients (24 male and 55 female) were included in the study, with their informed consent. Plasma samples and genomic DNA of the peripheral blood mononuclear cells were isolated and the provirus load was estimated by semi-quantitative polymerase chain reaction of the gag region sequence. Serum levels of anti-HTLV-1 antibodies and soluble IL-2R were determined by electrochemiluminescence immuno assay and by ELISA, respectively. Disease activities were assessed and graded 0 to 4 according to the evaluation system. Recurrence of the disease during the follow-up period was diagnosed ophthalmologically. The provirus load was significantly higher in the HU patients after Graves’ disease (GD) than in those without GD (P <<0.05). It correlated with disease activities assessed in terms of vitreous inflammation and interval to recurrence (both P <<0.05). In the HU patients without GD, it correlated with the serum levels of soluble IL-2 receptor (P <<0.01), and nearly with those of HTLV-1 antibody (P=0.063). These correlations were not found in the HU patients after GD under methimazole treatment. The results suggested a direct involvement of HTLV-1-infected cells in the pathogenesis of uveitis, and raise the possibility that hyperthyroidism may contribute to the clonal expansion of HTLV-1-infected cells.

Key words: HTLV-1 uveitis — Provirus load — Graves’ disease — Disease activities — sIL-2R

Human T-cell leukemia virus type 1 (HTLV-1) uveitis (HU) is an acute or subacute and recurrent uveitis characterized by T lymphocyte infiltration in the eye, particularly in the vitreous body, and production of interleukin (IL)-6 by the infiltrating cells.1-6 It is associated with Graves’ disease (GD) at an extraordinarily high rate.7 Actually, one-fourth of female patients have a history of GD.8, 9 Subsequent reports have confirmed our observation that, in all the patients, hyperthyroidism preceded the onset of HU,1,6, 9 which we described as HU after GD.10 The chronological order of the onsets of these two diseases and the lack of epidemiological evidence for association between HTLV-1-infection and Graves’ disease provide further evidence for the possible roles of hyperthyroidism or methimazole (MMI) or both in the development of HU, though the nature of these roles remains to be investigated.

The population of HTLV-1-infected cells, i.e., the provirus load, in the peripheral blood mononuclear cells (PBMC) was significantly higher in HU patients than in asymptomatic carriers.10 An increased provirus load has also been reported in tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM).11-16 Thus, it was suggested that the increased provirus load of HTLV-1 may be one factor in the development of inflammatory disorders caused by HTLV-1. It has also been reported that the proviral load correlates with immunologic parameters such as the serum levels of HTLV-1 antibodies and soluble IL-2 receptor (sIL-2R).17-24 Recent reports on the analysis of the integration sites of HTLV-1 provirus suggested that the increased provirus load results from clonal proliferation of the HTLV-1-infected cells, rather than virus replication and re-infection in vivo.25 However, the mechanism underlying the clonal expansion of the HTLV-1-infected cells and its relevance to the pathogenesis and pathophysicsology of HTLV-1-associated diseases remain to be delineated.

In the current study, we investigated the correlation between the provirus load in the PBMC of patients with HU and clinical and immunologic parameters, in order to obtain insight into the clinical and immunologic relevance of the provirus load as well as the mechanisms underlying...
the clonal expansion of the virus-infected cells. We found that the provirus load was significantly higher in patients after GD than in those without GD, and it generally correlated with disease activities and serum levels of HTLV-1 antibody and sIL-2R.

MATERIALS AND METHODS

Patients Diagnosis of HU was made according to the criteria described previously. Briefly, HTLV-1 seropositive patients with uveitis of unknown etiology after extensive ophthalmologic and laboratory examinations were diagnosed as HU. Seventy-nine patients (24 male and 55 female) were included in the study. Disease activities were assessed and graded into 0 to 4 according to the system proposed by Nussenblatt et al. for the evaluation of vitreal inflammatory activity in patients with uveitis. Recurrence of the disease during the follow-up period was diagnosed ophthalmologically. Among 79 patients with HU, 19 (all female) developed HU after GD and were under treatment with MMI. Thyroid function tests showed that all these patients were in an euthyroid state when they were enrolled in the study. Peripheral blood samples were collected after informed consent had been obtained from the patients. The principles embodied in the Declaration of Helsinki have been adhered to by the authors.

Semi-quantitative polymerase chain reaction (PCR) of HTLV-1 provirus Our assay system for the HTLV-1 provirus load in PBMC has been described previously. Briefly, PBMC samples were isolated by density gradient centrifugation using “Ficoll-Paque” (Pharmacia, Uppsala, Sweden). High-molecular-weight genomic DNA of the PBMC was extracted by means of proteinase K digestion and phenol/chloroform extraction. Using 0.5 µg genomic DNA samples as templates, HTLV-1 provirus copies were determined by semi-quantitative PCR of the gag region of the provirus.

Measurement of the serum levels of antibodies to HTLV-1 and sIL-2R The serum level of anti-HTLV-1 antibody was determined by the use of an electrochemiluminescence immuno assay (ECLIA) developed by Eisai Co., Ltd., Tokyo. Briefly, magnetic microparticles (Dynabeads M-450, Dynal A/S, Oslo, Norway) coupled with a combination of viral antigen purified from culture supernatant of MT-2 cell line and synthetic envelope (gp46) peptide antigen were used as a solid support. Absorbed antibodies were detected by electrochemically generated luminescence with the sandwich method using anti-human IgG (Fc) monoclonal antibody (Wako Junyaku, Osaka) coupled with ruthenium (II) tris (bipyridyl); Ru(bpy)₃. The antibody level of each serum sample was expressed as a cut-off index value (C.O.I.) which is the relative level of electroluminescence compared with that of the cut-off control. C.O.I. levels between 1 and 2 were considered indeterminate, and those above 2.0 positive. Results of the ECLIA method were compared with those of the ELISA method (New Eitest ATL, Eisai, Tokyo) using 280 ELISA-positive samples collected from 77 patients with ATL, 43 with TSP/HAM and 160 asymptomatic carriers and 441 ELISA-negative samples. All the 280 ELISA-positive serum samples were shown to be positive by the ECLIA method, and 98.2% of the 441 ELISA-negative serum samples showed negative.

The serum level of sIL-2R was determined by ELISA (T Cell Sciences Inc., Cambridge, Mass.).

Statistical methods Logarithmic scale transformation of the values of provirus load, interval to recurrence and serum levels of anti-HTLV-1 antibody and sIL-2R was conducted, and the converted variables proved to be approximately normally distributed. Associations between the parameters of interest were examined by the use of Pearson’s correlation coefficient (denoted by r) and linear regression analysis. The significance of differences between means was assessed by the use of Student’s t test.

RESULTS

Provirus load in patients with HU As we have previously reported, the provirus load was expressed as a percentage of the HTLV-1-infected cells in the PBMC on the assumptions that a single copy of HTLV-1 provirus is integrated in the infected T cells in vivo, and that 0.5 µg of genomic DNA corresponds to 0.75x10⁶ cells. The mean±SD of the provirus load in the PBMC of 79 patients with HU was 3.9±4.1%, which accords well with our previous results. Because all the patients after Graves’ disease in this study were female, we compared the provirus load of the female patients with HU, dividing them into those after GD (n=19) and those without GD (n=36). The geometric mean (anti-log(mean–SD)+anti-log(mean+SD)) values in the patients after GD or without GD were 3.27 (1.11–9.61) and 1.36 (0.29–6.25), respectively (Fig. 1). The difference was statistically significant (P<0.05), indicating that the HU patients after GD have a higher provirus load than those without GD.

Provirus load and activity of the uveitis HU is characterized by vitreous infiltration of inflammatory cells and a recurrent clinical course. Therefore, to investigate the relevance of the increased provirus load to clinical manifestations, the intensity of the vitreous inflammation and the frequency of recurrence were used as clinical parameters that indicate disease activities.

When vitreous inflammation was used as a clinical parameter, 14 patients with HU of anterior uveitis type were excluded from the study because vitreous inflammation is not a good indicator for the disease activity in these patients. The provirus load of 65 HU patients was
plotted against the level of vitreous inflammation graded 0 to 4 according to the evaluation system (Fig. 2). A significant correlation was found between the provirus load and the level of vitreous inflammation ($r=0.341$, $P<0.01$).

Recurrence of the uveitis was observed in 34 out of 54 patients (63.0%) who were clinically followed for more than 18 months. The relationship between the provirus load and the interval to recurrence is shown in Fig. 3. A significant but inverse correlation between these parameters was demonstrated ($r=-0.351$, $P<0.05$).

**Provirus load and serum levels of HTLV-1 antibody and sIL-2R** No correlation was found between the provirus load and the serum level of HTLV-1 antibody when analyzed in all the HU patients as a whole. Because patients after GD were all under treatment with MMI, which suppresses B cell activity, we next investigated the correlation in 42 patients without GD. The concentrations of serum HTLV-1 antibody of these patients ranged from 5.5 to 314.6 C.O.I. with a mean±SD of 104.8±81.6. The provirus load showed some correlation with the serum level of HTLV-1 antibody, but this was not statistically significant (Fig. 4) ($r=0.289$, $P=0.063$).

The correlation between the provirus load and the serum level of sIL-2R was also investigated in the 42 patients without GD. The concentrations of serum sIL-2R

---

**Fig. 1.** HTLV-1 provirus load in the PBMC of the HU female patients after Graves’ disease (19 patients) or those without it (36 patients). The mean (log $x$)±SD (log $x$) values for the population of HTLV-1-infected cells were 0.51±0.47 and 0.13±0.66, respectively. The geometric mean (anti-log (mean+SD)–anti-log (mean–SD)) values were 3.27 (1.11–9.61) and 1.35 (0.29–6.25), respectively. The difference was statistically significant ($P<0.05$).

**Fig. 2.** Provirus load and the intensity of vitreous inflammation. The provirus load of 65 patients with HU was plotted against the level of vitreous inflammation graded 0 to 4. A significant correlation was found ($r=0.341$, $P<0.01$). The regression line is expressed as $Y=0.227+1.071X$ where $Y=\log(y)$ and $X=\log(x)$.

**Fig. 3.** Provirus load and the interval to recurrence. The interval to recurrence of 34 patients with HU who were followed for more than 18 months was plotted against the provirus load. A significant but inverse correlation was found ($r=-0.351$, $P<0.05$). The regression line is expressed as $Y=0.941–0.575X$ where $Y=\log(y)$ and $X=\log(x)$. 
ranged from 211.0 to 1,838 pg/ml with a mean±SD of 516.6±320.8 pg/ml. The provirus load showed a significant positive correlation with the serum level of sIL-2R ($r=0.332$, $P<0.05$) (Fig. 5).

These results suggested that in the HU patients the levels of antibody response to HTLV-1 antigens and activation of T cells in vivo are correlated with the level of provirus load, as was reported previously in asymptomatic carriers and patients with TSP/HAM.}

**DISCUSSION**

In the present study, we found that the provirus load is higher in HU patients after GD than in those without GD, and correlates with disease activities and serum levels of HTLV-1 antibody and sIL-2R.

Increased provirus load appears to be a common characteristic in patients with HU and those with TSP/HAM. It is considered to result from clonal expansion of the virus-infected cells, rather than virus replication and re-infection, although the mechanisms remain to be delineated. As to the virus genome, no disease-specific changes in nucleotide sequence have been found in proviruses isolated from patients with HTLV-1-related diseases and asymptomatic carriers. The existence of a significant difference in the provirus load between patients after GD and those without GD was statistically confirmed. The autoimmune background of the patients does not appear to be necessarily associated with an increased provirus load, because patients with Sjögren’s syndrome who were infected with HTLV-1 did not have an increased provirus load. It may be relevant that we have found activation of the HTLV-1 long terminal repeat by thyroid hormone in vitro (unpublished observation), since this could contribute to clonal expansion of the infected cells through induction of the viral transcriptional transactivator Tax. The effects of MMI on clonal expansion of the virus-infected cells remain to be investigated, although recent reports do not suggest a direct effect of MMI on T cells.

The present work has shown that the provirus load is correlated with disease activities. This observation linked the provirus load to clinical parameters for the first time, providing support for the idea that the circulating HTLV-1-infected T cells are directly involved in the pathogenesis of HU. One possible explanation for the way in which the increased provirus load is associated with disease activities would be that the larger number of HTLV-1-infected cells would provide more chances for them to infiltrate into tissues, because adhesion molecules and inflammatory cytokines that activate vascular endothelial cells are aberrantly upregulated and constitutively expressed in HTLV-1-infected cells. This notion is consistent with our observation of predominant T lymphocyte infiltration and accumulation of HTLV-1-infected cells in the affected eye of patients with HU.

The correlation between the HTLV-1 provirus load and serum antibody has been reported previously. In the...
present study, the provirus load showed a correlation with the serum level of HTLV-1 antibody, which was quantitatively measured with the ECLIA method. The positive correlation between them was also confirmed by non-parametric analysis. The results provided further evidence for the idea that an increased number of HTLV-1-infected cells would lead to increased challenge by virus antigens expressed in amounts proportional to the number of virus-infected cells, resulting in increased antibody response. In the HU patients after GD, however, no correlation was found between the provirus load and serum antibody (data not shown). This could be explained by administration of MMI. The provirus load showed a significant correlation with the serum level of sIL-2R in the HU patients without GD, but not in those after GD (data not shown). Although previous reports suggested that the level of sIL-2R correlates with the number of HTLV-1-infected cells, this is the first demonstration of the correlation based on the quantitative analysis of provirus load, and provides supporting evidence for the interpretation that the elevated level of sIL-2R in the HTLV-1-infected individuals is due to constitutive production by the HTLV-1-infected cells. On the other hand, Koukkou et al. reported that sIL-2R is elevated in hyperthyroid patients, irrespective of the etiology, and that the level of sIL-2R was downregulated by administration of MMI, probably through normalizing the level of thyroid hormones. Thus, our findings in the HU patients after GD in the present study are consistent with these observations and the interpretation thereof. Treatment with MMI would explain the lack of these correlations in the HU patients after GD, because, besides normalizing the thyroid status, MMI is reported to have suppressive effects on B and T cells in vivo, although the mechanisms involved are still unknown.

Taken together, the results in the present study underlie the importance of the increased provirus load in the pathogenesis of inflammatory diseases caused by HTLV-1, and suggest a possible mechanism for the increased provirus load in vivo and direct involvement of the HTLV-1-infected cells in the pathogenesis of HU.

ACKNOWLEDGMENTS

This work was supported in part by a Grant-in-Aid for Cancer Research to T. Watanabe, M. Mochizuki and K. Yamaguchi, a Grant-in-Aid for Encouragement of Young Scientists to A. Ono, and by a grant from the Health Sciences Foundation to M. Mochizuki, all from the Ministry of Education, Science and Culture, Japan, and by a grant from the Mitsubishi Foundation to M. Mochizuki.

(Received February 12, 1998/Revised April 2, 1998/Accepted April 8, 1998)

REFERENCES

1) Mochizuki, M., Watanabe, T., Yamaguchi, K., Takatsuki, K., Yoshimura, K., Shirao, M., Nakashima, S., Mori, S., Araki, S. and Miyata, N. HTLV-1 uveitis: a distinct clinical entity caused by HTLV-1. Jpn. J. Cancer Res., 83, 236–239 (1992).
2) Mochizuki, M., Watanabe, T., Yamaguchi, K., Tajima, K., Yoshimura, K., Nakashima, S., Shirao, M., Araki, S., Miyata, N. and Mori, S. An uveitis associated with human T-lymphotropic virus type 1 (HTLV-1): seroepidemiological, clinical and virological studies. J. Infect. Dis., 166, 943–944 (1992).
3) Mochizuki, M., Watanabe, T., Yamaguchi, K., Yoshimura, K., Nakashima, S., Shirao, M., Araki, S., Takatsuki, K., Mori, S. and Miyata, N. An uveitis associated with human T-lymphotropic virus type 1 (HTLV-1). Jpn. J. Ophthalmol., 114, 123–129 (1992).
4) Mochizuki, M., Tajima, K., Watanabe, T. and Yamaguchi, K. Human T lymphotropic virus type 1 uveitis. Br. J. Ophthalmol., 78, 149–154 (1994).
5) Yoshimura, K., Mochizuki, M., Araki, S., Miyata, N., Yamaguchi, K., Tajima, K. and Watanabe, T. Clinical and immunologic features of human T-cell lymphotropic virus type I uveitis. Am. J. Ophthalmol., 116, 156–163 (1993).
6) Ono, A., Mochizuki, M., Yamaguchi, K., Miyata, N. and Watanabe, T. Immunological and virological characterization of the primary infiltrating cells in the aqueous humor of HTLV-1 uveitis; accumulation of the HTLV-1-infected cells and constitutive expression of viral and IL-6 mRNAs. Invest. Ophthalmol. Visual Sci., 38, 676–689 (1997).
7) Yamaguchi, K., Mochizuki, M., Watanabe, T., Yoshimura, K., Shirao, M., Araki, S., Miyata, N., Mori, S., Kiyokawa, T. and Takatsuki, K. Human T lymphotropic virus type 1 uveitis after Graves’ disease. Br. J. Ophthalmol., 78, 163–166 (1994).
8) Ozawa, Y., Migita, M., Watanabe, T., Okuda, I., Takeshita, A., Takagi, A. and Shishiba, Y. Development of Graves’ ophthalmopathy and uveitis after radiiodine therapy for Graves’ disease in a patient with HTLV-1-associated myelopathy (HAM). Intern. Med., 33, 564–568 (1994).
9) Mizokami, T., Okamura, K., Kohno, T., Sato, K., Ikenoue, H., Kuroda, T., Inokuchi, K. and Fujishima, M. Human T-lymphotropic virus type I-associated uveitis in patients with Graves’ disease treated with methylmercaptoimidazole. J. Clin. Endocrinol. Metab., 80, 1904–1907 (1995).
Clinical Relevance of Virus Load in HU

10) Ono, A., Mochizuki, M., Yamaguchi, K., Miyata, N. and Watanabe, T. Increased number of circulating HTLV-I infected cells in peripheral blood mononuclear cells of HTLV-I uveitis patients: a quantitative polymerase chain reaction study. *Br. J. Ophthalmol.*, 79, 270–276 (1995).

11) Gessain, A., Barin, F., Vernant, J. C., Gout, O., Maurus, L., Calender, A. and de The, G. Antibodies to human T lymphotrophic virus type-I in patients with tropical spastic paraparesis. *Lancet*, ii, 407–410 (1985).

12) Osame, M., Usuku, K., Izumo, S., Iijichi, N., Ami, Y., Suga, T., Uchida, H. and Miwa, M. Quantitation of HTLV-1 provirus among seropositive blood donors: relation with antibody profile (HTLV-1)-infected T cells in HTLV-1-associated myelopathy: a new clinical entity. *Lancet*, i, 1031–1032 (1986).

13) Yoshida, M., Osame, M., Usuku, K., Matsumoto, M. and Igata, A. Viruses detected in HTLV-I-associated myelopathy and adult T-cell leukemia are identical in DNA blotting. *Lancet*, i, 1085–1086 (1987).

14) Yoshida, M., Osame, M., Kawai, H., Toitu, M., Kawasaki, N., Nishida, Y., Hiraki, Y., Takahashi, K., Nomura, K., Sonoda, S., Eiraku, N., Iijichi, S. and Usuku, K. Increased replication of HTLV-1 in HTLV-1-associated myelopathy. *Ann. Neurol.*, 26, 331–335 (1989).

15) Greenberg, S. J., Jacobson, S., Waldman, T. A. and McFarlin, D. E. Molecular analysis of HTLV-1 proviral integration and T cell receptor arrangement indicates that T cells in tropical spastic paraparesis are polyclonal. *J. Infect. Dis.*, 159, 741–744 (1989).

16) Gessain, A., Saal, F., Gout, O., Daniel, M. T., Flandrin, G., de The, G., Peries, J. and Siqua, F. High human T-cell lymphotrophic virus Type 1 proviral DNA load with polyclonal integration in peripheral blood mononuclear cells of French West Indian, Guianese and African patients with tropical spastic paraparesis. *Blood*, 75, 428–433 (1990).

17) Kira, J., Koyanagi, Y., Yamada, T., Itoyama, Y., Goto, I., Yamamoto, N., Sasaki, H. and Sakaki, Y. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. *Ann. Neurol.*, 29, 194–201 (1991).

18) Furukawa, Y., Fujisawa, J., Osame, M., Toita, M., Sonoda, S., Kubota, R., Iijichi, S. and Yoshida, M. Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-I)-infected T cells in HTLV-I-associated myelopathy (HAM-TSP). *Blood*, 80, 1012–1015 (1992).

19) Osame, M., Matsumoto, M., Usuku, K., Izumo, S., Iijichi, N., Ami, T., Tani, M. and Igata, A. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia like cells. *Ann. Neurol.*, 21, 117–122 (1987).

20) Matsumura, M., Kushida, S., Ami, Y., Suga, T., Uchida, K., Kameyama, T., Terano, A., Inoue, Y., Okochi, K., Sato, H. and Miwa, M. Quantitation of HTLV-I provirus among seropositive blood donors: relation with antibody profile using synthetic peptides. *Int. J. Cancer*, 55, 220–222 (1993).

21) Ishihara, S., Okayama, A., Stuber, S., Horinouchi, H., Shioiri, K., Murai, K., Kubota, R., Yamashita, R., Tachibana, N., Tsoubouchi, H. and Mueller, N. Association of HTLV-I antibody profile of asymptomatic carriers with proviral DNA levels of peripheral blood mononuclear cells. *J. Acquir. Immune Defic. Syndr.*, 7, 199–203 (1994).

22) Morand-Joubert, L., Mariotti, M., Reed, D., Petit, J.-C. and Lefrere, J.-J. Correlation between viral DNA load and serum anti p19 antibody concentration in symptomless human T-lymphotropic virus type-I (HTLV-I)-infected individuals. *Int. J. Cancer*, 60, 156–159 (1995).

23) Miyata, H., Kamahora, T., Iku, S., Katamine, S., Miyamoto, T. and Hino, S. Dependency of antibody titer on provirus load in human T lymphotropic virus type I carriers: an interpretation for the minor population of seronegative carriers. *J. Infect. Dis.*, 171, 1455–1460 (1995).

24) Yamaguchi, K., Nishimura, Y., Kiyokawa, T. and Takatsuki, S. Elevated serum levels of soluble interleukin-2 receptors in HTLV-1-associated myelopathy. *J. Lab. Clin. Med.*, 114, 407–410 (1989).

25) Wattel, E., Vartanian, J. P., Pannetier, C. and Wain-Hobson, S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. *J. Virol.*, 69, 2863–2868 (1995).

26) Nussenblatt, R. B., Palestine, A. G., Chan, C. and Roberge, F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. *Ophthalmology*, 92, 467–471 (1985).

27) Blackburn, G. F., Shah, H. P., Kenten, J. H., Leland, J., Kamin, R. A., Link, J., Peterman, J., Powell, M. J., Shah, A., Talley, D. B., Tyagi, S. K., Wilkins, E., Wu, T.-G. and Masrey, R. J. Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnosis. *Clin. Chem.*, 37/9, 1534–1539 (1991).

28) Namba, Y., Naraki, T., Watanabe, K., Yamane, S. and Mukojima, T. Studies on new immunoassay method using electrochemiluminescence (ECL). *Jpn. J. Clin. Lab. Assoc.*, 21, 680–686 (1996) (in Japanese).

29) Wilson, R., McKillop, J. H., Chopra, M. and Thompson, J. A. The effect of antithyroid drugs on B and T cell activity in vitro. *Clin. Endocrinol.*, 28, 389–397 (1988).

30) Karlsson, F. A. and Totterman, T. H. Immunomodulation by methimazole therapy in Graves’ disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells. *Clin. Exp. Immunol.*, 74, 258–263 (1988).

31) Daenke, S., Nightingale, S., Cruickshank, J. K. and Bangham, C. R. Sequence variants of human T-cell lymphotrophic virus Type I tax gene within a family cluster showing complete sequence conservation of the human T cell leukemia virus type I tax gene sequence. *J. Virol.*, 54, 220–222 (1987).

32) Nishimura, M., McFarlin, D. E. and Jacobson, S. Comparison of HTLV-I from HAM/TSP patients and their asymptomatic spouses. *Clin. Endocrinol.*, 22, 194–201 (1985).

33) Major, M. E., Nightingale, S. and Desselberger, U. Complete sequence conservation of the human T cell leukemia virus type I tax gene within a family cluster showing dif-
ferent pathologies. *J. Gen. Virol.*, **74**, 2531–2537 (1993).

34) Ono, A., Miura, T., Araki, S., Yamaguchi, K., Takatsuki, K., Mori, S., Hayami, M., Mochizuki, M. and Watanabe, T. Subtype analysis of HTLV-1 in patients with HTLV-1 uveitis. *Jpn. J. Cancer Res.*, **85**, 767–770 (1994).

35) Terada, K., Katamine, S., Eguchi, K., Moriuchi, M., Kita, H., Shimada, I., Yamashita, K., Iwata, Y., Tsuji, S., Nagataki, S. and Miyamoto, T. Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren’s syndrome. *Lancet*, **344**, 1116–1119 (1994).

36) Bagnasco, M., Venuti, D., Ciprandi, G., Pesce, G., Paolieri, F. and Canonica, G. W. The effect of methimazole on the immune system is unlikely to operate directly on T lymphocytes. *J. Endocrinol. Invest.*, **13**, 493–499 (1990).

37) Escobar-Morreale, H. F., Serrano-Gotarredona, J., Villar, L. M., Garcia-Robles, R., Gonzalez-Porque, P., Sancho, J. M. and Varela, C. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves’ disease. *Thyroid*, **6**, 29–36 (1996).

38) Dhawan, S., Weeks, B., Abbasi, F., Gralnick, H. R., Notkins, A. L., Klotman, M. E., Yamada, K. M. and Klotman, P. E. Increased expression of ε4β1 and ε5β1 integrins on HTLV-1 infected lymphocytes. *Virology*, **197**, 778–781 (1993).

39) Imai, T., Tanaka, Y., Fukudome, K., Takagi, S., Araki, K. and Yoshie, O. Enhanced expression of LFA-3 on human T-cell lines and leukemic cells carrying human T-cell leukemia virus type I. *Int. J. Cancer*, **55**, 811–816 (1993).

40) Fukudome, K., Furuse, M., Fukuhara, N., Orita, S., Imai, T., Takagi, S., Nagira, M., Hinuma, Y. and Yoshie, O. Strong induction of ICAM-1 in human T cells transformed by human T cell leukemia virus type I and depression of ICAM-1 or LFA-1 in adult T cell leukemia derived cell lines. *Int. J. Cancer*, **52**, 418–427 (1992).

41) Tatewaki, M., Yamaguchi, K., Matsuoka, M., Ishii, T., Miyasaka, M., Mori, S., Takatsuki, K. and Watanabe, T. Constitutive overexpression of the L-selectin gene in fresh leukemic cells of adult T-cell leukemia that can be transactivated by human T-cell lymphotropic virus type I Tax. *Blood*, **86**, 3109–3117 (1995).

42) Sagawa, K., Mochizuki, M., Masuoka, K., Katagiri, K., Katayama, Y., Maeda, T., Tanimoto, A., Sugita, S., Watanabe, T. and Itoh, K. Immunopathological mechanisms of human T-cell lymphotropic virus type I (HTLV-I) uveitis: detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production. *J. Clin. Invest.*, **95**, 852–858 (1995).

43) Mori, N. and Prager, D. Transactivation of the interleukin-1 alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. *Blood*, **87**, 3410–3417 (1996).

44) Albrecht, H., Shakhoz, A. N. and Jongeneel, C. V. Transactivation of the tumor necrosis factor alpha promoter by the human T-cell leukemia virus type I Tax protein. *J. Virol.*, **66**, 6191–6193 (1992).

45) Furukawa, Y., Osame, M., Kubota, R., Tara, M. and Yoshida, M. Human T-cell leukemia virus type-I (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic para-paresis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. *Blood*, **85**, 1865–1870 (1995).

46) Inoue, Y., Kuroda, N., Shiraki, H., Sato, H. and Maeda, Y. Neutralizing activity of human antibodies against the structural protein of human T-cell lymphotropic virus type I. *Int. J. Cancer*, **52**, 877–880 (1992).

47) Iwahara, Y., Sawada, T., Taguchi, H., Hoshino, H., Umemoto, M., Take, H., Foun, S. and Miyoshi, I. Neutralizing antibody to vesicular stomatitis virus (HTLV-I) pseudotype in infants born to seropositive mothers. *Jpn. J. Cancer Res.*, **84**, 114–116 (1993).

48) Desgrange, C., Souche, S., Vernant, J. C., Smadja, D., Vahe, A. and Horal, P. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera. *AIDS Res. Hum. Retroviruses*, **10**, 163–173 (1994).

49) Kamihira, S., Atogami, S., Soida, H., Morita, S., Yamada, Y. and Tomonaga, M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. *Cancer*, **74**, 2753–2758 (1994).

50) Inoue, J., Seiki, M., Taniguchi, T., Tsuru, S. and Yoshida, M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type I. *EMBO J.*, **5**, 2883–2887 (1986).

51) Matsumoto, M., Sugimoto, M., Nakashima, H., Imamura, F., Kawano, O., Uyama, E., Takatsu, K. and Araki, S. Spontaneous T cell proliferation and release of soluble interleukin-2 receptors in patients with HTLV-I-associated myelopathy. *Am. J. Trop. Med. Hyg.*, **42**, 365–373 (1990).

52) Koukkou, E., Panayiotidou, P., Alexiou-Tzarakis, V. and Thalassinis, N. High levels of serum soluble interleukin 2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. *J. Clin. Endocrinol. Met.*, **73**, 771–776 (1991).